Next Generation Weight Loss Drugs: What Is Coming After GLP-1

The success of semaglutide and tirzepatide triggered an arms race in obesity drug development. After tirzepatide proved that hitting two receptors (GLP-1 and GIP) was better than one, pharmaceutical companies started asking: what if we hit three receptors? What if we added another mechanism entirely? The result is a pipeline with more active obesity drug candidates than at any point in history. Over 100 anti-obesity medications are in clinical development as of 2026. The most advanced candidates are in phase 3 trials or have completed them. The strategies fall into a few categories. Multi-receptor agonists hit GLP-1 plus GIP plus glucagon, or GLP-1 plus glucagon. Oral formulations remove the injection barrier. Combination therapies stack two drugs with different mechanisms. Novel targets explore pathways like amylin, myostatin, and leptin sensitization. This is not a speculative future. Several of these drugs will likely be approved within the next 1 to 3 years. Some may be available through compounding pharmacies sooner, depending on regulatory timelines.

Each next-generation drug has a distinct mechanism. Here is what each one targets.

Here are the weight loss results from the latest clinical trial data.

No one outside of clinical trials has used retatrutide yet. But based on the mechanism, we can anticipate what these drugs will feel like. Triple agonists like retatrutide will likely have a similar appetite suppression profile to tirzepatide but with greater metabolic effects. The glucagon component may cause more initial side effects since glucagon raises blood sugar acutely before the GLP-1 and GIP components compensate. Trial participants reported nausea and diarrhea during dose escalation, similar to existing GLP-1 drugs. Oral drugs like orforglipron will change the user experience entirely. No needles, no reconstitution, no refrigeration. Just take a pill once daily. The convenience factor alone will drive adoption. Side effects are expected to mirror injectable GLP-1 drugs. A user on r/Mounjaro who participated in a clinical trial for a next-gen compound shared: “Cannot say which drug, but it is in the pipeline. Appetite suppression was stronger than what I experienced on Mounjaro. Lost about 8 percent body weight in 12 weeks. Side effects were manageable, mostly nausea in the first month. Excited for this to come to market.“

• Greater weight loss potential, possibly 25 to 30 percent body weight with triple agonists
• Oral options that eliminate the need for injections
• Better metabolic outcomes beyond weight loss, including improved blood sugar and liver fat reduction
• Potentially fewer side effects through smarter receptor targeting
• Options for people who did not respond well to current GLP-1 drugs

Once approved, the same stacking principles will apply. Pipeline GLP-1/GIP/glucagon drugs will pair well with AOD-9604 for stubborn fat, MOTS-c for metabolic support, and GH peptides for muscle preservation. The core strategy of appetite suppression plus metabolic optimization plus muscle protection remains relevant regardless of which drug handles the appetite suppression. BPC-157 will likely be a useful adjunct for managing GI side effects, as it is with current GLP-1 drugs. The main change will be that fewer people need to stack multiple weight loss peptides, because a single triple agonist may cover appetite suppression, fat oxidation, and metabolic improvement in one molecule.